Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for refractory lymphoma: tailored drug cocktail targets resistant cancer

NCT ID NCT07493330

Disease control Sponsor: Ruijin Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new approach for people with a type of lymphoma (PTCL) that did not respond to initial chemotherapy. Doctors will use genetic testing of the tumor to choose a personalized combination of drugs, including an experimental drug called zeprumetostat. The goal is to see if this tailored treatment can shrink or control the cancer. About 86 adults will take part in this early-phase study.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 86 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years, male or female. * Patients with a histopathologically confirmed diagnosis of peripheral T-cell lymphoma (PTCL) based on 2016 WHO classification * Previously treated with 3 or 6 cycles of a CHOP-like regimen as first-line therapy and considered primary refractory. Patients with anaplastic large cell lymphoma (ALCL) must have adequately received brentuximab vedotin (BV) as part of their first-line treatment. * Tumor tissue genotyping performed and results available prior to enrollment. * ECOG 0, 1, or 2. * Life expectancy greater than 3 months. * Adequate organ function * Contraception during study * Informed consented Exclusion Criteria: * Has a prior malignancy other than the malignancies under study within 3 years without relieve * Primary CNS lymphoma * Known hypersensitivity to any study drug. * Pregnant or lactation * Active infection. * Diseases and medical history: 1. Requires continuous treatment with strong or moderate CYP3A inhibitors or CYP3A inducers 2. Has multiple factors affecting oral medication administration (e.g., inability to swallow, chronic diarrhea, intestinal obstruction, etc.); 3. Has a history of psychoactive substance abuse that cannot be discontinued 4. Has any severe and/or uncontrolled disease. * Uncontrollable autoimmune disease, * Not able to comply to the protocol for mental or other unknown reasons * Any other condition that, in the investigator's judgment, makes the patient unsuitable for study participation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PTCL are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

mature T-cell and NK-cell non-Hodgkin lymphoma peripheral T-cell lymphoma, not otherwise specified

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PTCL Refractory

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.